IPSO pounces on Cambridge Meditech technology

IPSO Ventures Plc, an intellectual property commercialisation specialist, has acquired Cambridge Meditech in a cash-and-shares deal worth £50,000.


IPSO Ventures Plc, an intellectual property commercialisation specialist, has acquired Cambridge Meditech in a cash-and-shares deal worth £50,000.

IPSO Ventures Plc, an intellectual property commercialisation specialist, has acquired Cambridge Meditech in a cash-and-shares deal worth £50,000. The payment will be satisfied through 77,000 shares and the cash repayment of directors’ loans worth £18,500.

The strategic rationale of the deal is a Cambridge Meditech technology that can detect infection in wounds. This patent-protected technology will enable IPSO to develop a range of products for the healthcare market.

This technology also complements the work IPSO is doing in investee company, Medermica, which specialises in dermatological skincare treatments.

Simon Hunt, Executive Chairman of IPSO, commented: “We are pleased to have the opportunity to acquire this interesting technology, which complements the work we are doing in our investee company, Medermica.”

Marc Barber

Raven Connelly

Marc was editor of GrowthBusiness from 2006 to 2010. He specialised in writing about entrepreneurs, private equity and venture capital, mid-market M&A, small caps and high-growth businesses.

Related Topics

Venture capital funding